Search results for "colorectal neoplasms"

showing 10 items of 496 documents

Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicen…

2019

Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] and cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies. Methods PSC-IBD patients were identified from the Spanish ENEIDA registry of GETECCU. Additional data were collected using the AEG-REDCap electronic data capture tool. Results In total, 277 PSC-IBD patients were included, with an incidence rate of 61 PSC cases per 100 000 IBD patient-years, 69.7% …

AdultMalemedicine.medical_specialtyendocrine system diseasesColorectal cancerCholangitis SclerosingRisk AssessmentGastroenterologyInflammatory bowel diseasedigestive systemPrimary sclerosing cholangitisCholangiocarcinomaBile Ducts ExtrahepaticRisk FactorsInterquartile rangeinflammatory bowel diseaseInternal medicineHumansMedicineRetrospective Studiesbusiness.industryPrimary sclerosing cholangitisHazard ratiodigestive oral and skin physiologyGastroenterologyRetrospective cohort studyGeneral MedicineOdds ratioMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurvival AnalysisUlcerative colitisdigestive system diseasesPatient Care ManagementBile Ducts IntrahepaticSpainFemalePrimary sclerosing cholangitis inflammatory bowel disease malignancyColorectal Neoplasmsbusinessmalignancy
researchProduct

5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Souther…

2000

The combination regimen CPT-11 plus bolus and infusion 5-fluorouracil (5-FU) with high-dose leucovorin (hybrid regimen LV5FU2) has been tested for activity and toxicity against advanced colorectal carcinoma in a randomised, multicenter phase II trial.A total of 102 chemotherapy-naïve patients were randomised in a 1:2 fashion to receive: leucovorin 100 mg/m2 administered as a two-hour infusion before 5-FU 400 mg/m2 as an intravenous bolus, and FU 600 mg/m2 as a 22-hour infusion immediately after 5-FU bolus injection repeated on days 1 and 2 (LV5FU2 regimen, arm A, 34 patients) or CPT-11 at 180 mg/m2 (150 mg/m2 for patients of ageor = 70 and75 years) only on day 1 immediately before LV5FU2 th…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLeucovorinPhases of clinical researchIrinotecanGastroenterologyDisease-Free SurvivalFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedChemotherapybusiness.industryHematologyMiddle AgedChemotherapy regimenSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracilInjections IntravenousCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Perceived barriers to and facilitators of being physically active during adjuvant cancer treatment

2016

The aim was to describe cancer patients' perceived barriers and facilitators of physical activity during adjuvant cancer treatment.Semi-structured focus group interviews were conducted with patients with breast cancer (n=9) and colorectal cancer (n=1) and prostate cancer (n=8) undergoing adjuvant cancer treatment. To capture perceived barriers and facilitators before starting treatment, individual interviews with women with breast cancer (n=5) were also conducted. 23 patients in total, were interviewed, and the transcribed interviews were analysed with qualitative content analysis.Three categories emerged: "Physical and emotional barriers"-addresses experiences of side-effects, co-morbid co…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhysical activityAlternative medicineBreast NeoplasmsMotor ActivityInterviews as Topic03 medical and health sciences0302 clinical medicineNursingmedicineHumans030212 general & internal medicineExerciseQualitative ResearchAgedSwedenMotivationbusiness.industryProstatic NeoplasmsCancerGeneral MedicineFocus GroupsMiddle Agedmedicine.diseaseCombined Modality TherapyFocus groupSelf ConceptCancer treatmentChemotherapy Adjuvant030220 oncology & carcinogenesisFemalePerceptionRadiotherapy AdjuvantColorectal NeoplasmsbusinessAdjuvantPatient Education and Counseling
researchProduct

VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab

2008

AIM: To gain mechanistic insights into the role played by epidermal growth factor receptor (EGFR) in the regulation of vascular endothelial growth factors (VEGFs) in colorectal cancer (CRC). METHODS: The impact of high-level expression of the growth factor receptors EGFR and VEGF receptor (VEGFR)3 and the VEGFR3 ligands VEGF-C and VEGF-D on disease progression and prognosis in human CRC was investigated in 108 patients using immunohistochemistry. Furthermore, the expression of the lymphangiogenic factors in response to the modulation of EGFR signalling by the EGFR-targeted monoclonal antibody cetuximab was investigated at the mRNA and protein level in human SW480 and SW620 CRC cell lines an…

AdultPathologymedicine.medical_specialtyColorectal cancerTransplantation HeterologousVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DCetuximabAntineoplastic AgentsMice SCIDAntibodies Monoclonal HumanizedMiceGrowth factor receptorMice Inbred NODCell Line TumorMedicineAnimalsHumansEpidermal growth factor receptorneoplasmsAgedColorectal CancerAged 80 and overCetuximabbiologyintegumentary systembusiness.industryGastroenterologyVascular Endothelial Growth Factor DAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseVascular Endothelial Growth Factor Receptor-3digestive system diseasesLymphangiogenesisErbB ReceptorsVascular endothelial growth factor CCancer researchbiology.proteinImmunohistochemistryFemalebusinessColorectal NeoplasmsNeoplasm Transplantationmedicine.drugSignal Transduction
researchProduct

Long-term evaluation of quality of life and gastrointestinal well-being after segmental colo-rectal resection for deep infiltrating endometriosis (EN…

2019

Purposes: The primary objective is to assess the long-term quality of life (QoL) and gastrointestinal well-being in patients with endometriosis (DIE) who underwent segmental resection (SR), through specific questionnaires focused on endometriosis and specific gastrointestinal evaluation. The secondary objectives are represented by the evaluation of peri-operative and post-operative outcomes of the procedure. Methods: This observational cohort study ENDO-RESECT (ClinicalTrials.gov ID: NCT03824054) reports all clinical data about women who underwent SR for DIE between October 2005 and November 2017. In the part of the study dedicated to the QoL assessment, the questionnaires adopted were the …

AdultQuality of lifemedicine.medical_specialtyAbdominal painConstipationAdolescentGastrointestinal DiseasesEndometriosisEndometriosisSegmental colo-rectal resectionHospital Anxiety and Depression ScaleGastrointestinal symptomsCohort StudiesYoung AdultPostoperative ComplicationsQuality of lifePregnancySurveys and QuestionnairesInternal medicineGastrointestinal symptommedicineHumansDeep infiltrating endometriosis; Gastrointestinal symptoms; Intestinal endometriosis; Personalized medicine; Quality of life; Segmental colo-rectal resection; Adolescent; Adult; Cohort Studies; Colorectal Neoplasms; Endometriosis; Female; Gastrointestinal Diseases; Humans; Middle Aged; Postoperative Complications; Pregnancy; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Young Adultbusiness.industryIntestinal endometriosiObstetrics and GynecologyGeneral MedicineMiddle Agedmedicine.diseasePersonalized medicineDeep infiltrating endometriosiTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIADeep infiltrating endometriosisDeep infiltrating endometriosis; Intestinal endometriosis; Segmental colo-rectal resection; Quality of life; Gastrointestinal symptoms; Personalized medicineDefecationFemaleIntestinal endometriosisSegmental resectionmedicine.symptomColorectal NeoplasmsbusinessCohort study
researchProduct

A new 8-oxo-7,8-2 ' deoxyguanosine nanoporous anodic alumina aptasensor for colorectal cancer diagnosis in blood and urine

2021

Many important human diseases, and especially cancer, have been related to the overproduction of 8-oxo-7,8-dihydro-2 '-deoxyguanosine (8-oxo-dG). This molecule is a product of oxidative stress processes over nucleophilic bases in DNA. In this work, an aptasensor for the rapid, selective and accurate detection of this oncomarker is presented. The aptasensor consists of a nanoporous anodic alumina material loaded with a dye and is functionalized with an aptamer-based "molecular gate". In the presence of target 8-oxo-dG, the capping aptamer displaces from the surface due to the high affinity of the analyte with the capping aptamer, thus inducing delivery of the preloaded fluorescent dye. In co…

AnalyteChromatographyNanoporousColorectal cancerChemistryAptamerDeoxyguanosineCancerUrinemedicine.diseaseFluorescenceNanoporeschemistry.chemical_compound8-Hydroxy-2'-DeoxyguanosineAluminum OxidemedicineHumansDeoxyguanosineGeneral Materials ScienceColorectal Neoplasms
researchProduct

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

2015

How dying tumor cells get noticed Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and ov…

AnthracyclineColorectal cancermedicine.medical_treatmentT-LymphocytesBreast Neoplasmsmicrofluidic chipchemotherapyPolymorphism Single NucleotideFormyl peptide receptor 1immune responseMiceImmune systemImmunityCell Line TumorNeoplasmsmedicineLeukocytesAnimalsHumansAnthracyclinesAllelesAnnexin A1ChemotherapyMultidisciplinarybusiness.industryDendritic Cellsmedicine.diseaseReceptors Formyl PeptideImmunity InnateChemotherapy AdjuvantCancer cellImmunologyCancer researchFemalebusinessColorectal NeoplasmsAdjuvantFPR1 microfluidicScience (New York, N.Y.)
researchProduct

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

2007

Angiogenesis is the process by which new blood vessels are created from pre-existing vessels. It is essential for the growth and development of normal cells and tissues during embryonic and neonatal development and of tumour cells. Solid tumours rely on having an extensive network of blood vessels for growth and survival. The key mediator of angiogenesis, vascular endothelial growth factor-A (VEGF-A), is critical for the growth of tumours and their subsequent metastasis and is known to initiate angiogenesis. Bevacizumab is a humanized immunoglobulin G monoclonal antibody that binds to VEGF with high specificity, thereby blocking VEGF-mediated signalling pathways and thus angiogenesis. Clini…

Antimetabolites AntineoplasticBevacizumabColorectal cancerAngiogenesisNeovascularization PhysiologicAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMetastasisNeovascularizationchemistry.chemical_compoundHumansMedicineDrug InteractionsPharmacology (medical)Neoplasm MetastasisSurvival ratePharmacologybusiness.industryAntibodies Monoclonalmedicine.diseaseBevacizumabSurvival RateVascular endothelial growth factorchemistryImmunologyMonoclonalCancer researchDrug Therapy CombinationFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct

Revisiting the thiosemicarbazonecopper(II) reaction with glutathione. Activity against colorectal carcinoma cell lines.

2018

Thiosemicarbazones (TSCs), and their copper derivatives, have been extensively studied mainly due to the potential applications as antitumor compounds. A part of the biological activity of the TSC-CuII complexes rests on their reactivity against cell reductants, as glutathione (GSH). The present paper describes the structure of the [Cu(PTSC)(ONO2)]n compound (1) (HPTSC =pyridine-2-carbaldehyde thiosemicarbazone) and its spectroscopic and magnetic properties. ESI studies performed on the reaction of GSH with 1 and the analogous [{Cu (PTSC*)(ONO2)}2] derivative (2, HPTSC* =pyridine-2-carbaldehyde 4N-methylthiosemicarbazone) show the absence of peaks related with TSC-Cu-GSH species. However GS…

Aparato digestivo-EnfermedadesThiosemicarbazonesSpectrometry Mass Electrospray IonizationColorectal cancerColon carcinoma010402 general chemistryCrystallography X-RayThiosemicarbazone01 natural sciencesBiochemistryInorganic Chemistrychemistry.chemical_compoundColon carcinomaCell Line TumorSpectroscopy Fourier Transform InfraredmedicineHumansMolecular magnetismDigestive organs-DiseasesMolecular Structure010405 organic chemistryChemistryMyoglobinCytochromes cGlutathioneChemistry Inorganicmedicine.diseaseMolecular biologyGlutathioneQuímica inorgánica0104 chemical sciencesCell cultureDrug Screening Assays AntitumorColorectal NeoplasmsCopperJournal of inorganic biochemistry
researchProduct

Extensive transcriptional complexity during hypoxia-regulated expression of the myoglobin gene in cancer.

2013

Recently, the ectopic expression of myoglobin (MB) was reported in human epithelial cancer cell lines and breast tumor tissues, where MB expression increased with hypoxia. The better prognosis of MB-positive breast cancer patients suggested that the globin exerts a tumor-suppressive role, possibly by impairing mitochondrial activity in hypoxic breast carcinoma cells. To better understand MB gene regulation in cancer, we systematically investigated the architecture of the human MB gene, its transcripts and promoters. In silico analysis of transcriptome data from normal human tissues and cancer cell lines, followed by RACE-PCR verification, revealed seven novel exons in the MB gene region, mo…

Breast NeoplasmsBiologyAdenocarcinomamedicine.disease_causeTranscriptomeExonMiceCell Line TumorGeneticsmedicineCoding regionAnimalsHumansPromoter Regions GeneticMolecular BiologyGeneGenetics (clinical)PhylogenyRegulation of gene expressionMyoglobinPromoterGeneral MedicineExonsMolecular biologyCell HypoxiaMitochondriaGene Expression Regulation NeoplasticAlternative SplicingEctopic expressionFemaleCarcinogenesisColorectal NeoplasmsTranscriptomeHuman molecular genetics
researchProduct